Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olmesartan medoxomil + calcium channel blocker
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Olmesartan medoxomil + calcium channel blocker (CCB) is a combination antihypertensive therapy developed by Daiichi Sankyo. It consists of olmesartan medoxomil, a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II type 1 (AT1) receptor antagonist, and a dihydropyridine calcium channel blocker (typically amlodipine). Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 receptor in vascular smooth muscle and the adrenal gland. The CCB component inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in vasodilation and decreased peripheral vascular resistance. This combination is primarily indicated for the treatment of essential hypertension, particularly in patients whose blood pressure is not adequately controlled by monotherapy, providing additive blood pressure lowering through complementary mechanisms of action.
- Brand names
- AzorSevikarRezaltas
- Other names
- olmesartan medoxomil + CCBolmesartan medoxomil and a CCBolmesartan medoxomil + calcium channel blocker
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR2 (AT2)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on olmesartan medoxomil + calcium channel blocker.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olmesartan medoxomil + calcium channel blocker.